Download PDF
Pharmacopsychiatry 2015; 48(04/05): 178-181
DOI: 10.1055/s-0035-1549997
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Reversible Amisulpride-induced Elevation of Creatine Kinase (CK): A Case Series from the German AMSP Pharmacovigilance Project

Z. G. Laoutidis
1   Department of Psychiatry and Psychotherapy, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
,
A. Konstantinidis
2   Department of Psychiatry and Psychotherapy, Division of Biological Psychiatry, Medical University Vienna, Austria
,
R. Grohmann
3   Department of Psychiatry, Ludwig Maximilian University of Munich, Germany
,
C. Luckhaus
1   Department of Psychiatry and Psychotherapy, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
,
J. Mobascher
1   Department of Psychiatry and Psychotherapy, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
,
J. Cordes
1   Department of Psychiatry and Psychotherapy, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
› Author Affiliations
Further Information

Publication History

received 05 December 2014
revised 08 April 2015

accepted 17 April 2015

Publication Date:
18 May 2015 (online)

Also available at
    Permissions and Reprints

Abstract

The elevation of creatine kinase (CK) levels without neuroleptic malignant syndrome has been reported for several antipsychotics. We present here 4 cases with CK elevation induced by amisulpride, which have been registered for the German pharmacovigilance project, Arzneimittelsicherheit in der Psychiatrie (AMSP). The magnitude of the CK elevation ranged between 1 498 IU/L and 21 018 IU/L. All 4 patients reported myalgia. In each case CK returned to normal after amisulpride discontinuation. In the fourth case, fluids were administered intravenously in order to prevent acute renal failure. None of the cases showed deterioration of renal function. Finally, we present recommendations for clinical practice.

Key words

amisulpride - antipsychotics - creatine kinase - rhabdomyolysis
 

  • References

  • 1 Laoutidis ZG, Kioulos KT. Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice. Psychopharmacology (Berl) 2014; 231: 4255-4270
    CrossrefPubMedGoogle Scholar
  • 2 Grohmann R, Engel RR, Rüther E et al. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004; 37 (Suppl. 01) S4-S11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Ursini F, Succurro E, Grembiale A et al. Acute rhabdomyolysis during treatment with amisulpride and metformin. Eur J Clin Pharmacol 2010; 66: 321-322
    CrossrefPubMedGoogle Scholar
  • 4 Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996; 15: 395-405
    CrossrefPubMedGoogle Scholar
  • 5 Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reaction. Clin Pharm Ther 1981; 30: 239-245
    PubMedGoogle Scholar
  • 6 Meltzer HY. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?. Psychopharmacology (Berl) 2000; 150: 349-350
    CrossrefPubMedGoogle Scholar
  • 7 Deravajan S, Dursun SM. Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms. Psychopharmacology (Berl) 2000; 152: 122
    CrossrefPubMedGoogle Scholar